Monday, 12th of August 2013 |
Sciencewww.sciencemag.org
Published Online August 8 2013
Research Article
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
the VRC 312 Study Team§
+ Author Affiliations
1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
2Sanaria, Rockville, MD 20850, USA.
3Protein Potential LLC, Rockville, MD 20850, USA.
4Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
5Entomology Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
6U.S. Military Malaria Vaccine Program, Naval Medical Research Center, Silver Spring, MD 20910, USA.
7Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892, USA.
8Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
9Howard Hughes Medical Institute, Baltimore, MD 21201, USA.
↵†Corresponding author. E-mail: rseder@mail.nih.gov
↵* These authors contributed equally to this work.
↵‡ These authors contributed equally to this work.
Abstract below and at http://www.sciencemag.org/content/early/2013/08/07/science.1241800; full text is available to journal subscribers.
Consistent high-level, vaccine-induced protection against human malaria has only been achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites. We report that the PfSPZ vaccine, composed of attenuated, aseptic, purified, cryopreserved PfSPZ, was safe and well-tolerated when administered 4 to 6 times intravenously (IV) to 40 adults. 0/6 subjects receiving 5 doses, 3/9 subjects receiving 4 doses of 1.35 x 105 PfSPZ vaccine, and 5/6 nonvaccinated controls developed malaria following controlled human malaria infection (P = 0.015 in the 5-dose group and P = 0.028 for overall, both versus controls). PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved by IV administration of a vaccine that is safe and meets regulatory standards.
↵§ The VRC 312 Study Team members are listed in the supplementary materials.
Received for publication 11 June 2013.
Accepted for publication 25 July 2013.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41192973 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |